A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
But breaking Pfizer and Merck’s duopoly will not be easy.
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.